|Bid||14.00 x 1000|
|Ask||14.80 x 800|
|Day's Range||14.75 - 15.25|
|52 Week Range||14.50 - 34.92|
|Beta (3Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
If you want to know who really controls KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), then you'll have to look at the...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality business to buy (at the right price) you canRead More...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
KalVista Pharmaceuticals (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...